Mersana Therapeutics, Inc. Profile Avatar - Palmy Investing

Mersana Therapeutics, Inc.

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clin…

Biotechnology
US, Cambridge [HQ]
Growth Rates · Payout · Yield

Dividends Over Time

  • Records
  • Forecasts [Soon]
Growth Rates
% YoY
% 3Yr
% 5Yr
% 10Yr
Key Metrics
- -% TTM Yield
- - Average Days Gap
Series
% - - Yield
0.00% Payout Ratio
Cash Amount Pay Date
Cash Amount Pay Date
End of MRSN's Analysis
CIK: 1442836 CUSIP: 59045L106 ISIN: US59045L1061 LEI: - UEI: -
Secondary Listings
MRSN has no secondary listings inside our databases.